TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All subjects enrolled in the BABY HUG Follow-Up I Study who participated for at least 24 months are eligible for the Follow-Up Study II~Exclusion Criteria:~* Subjects that have received a Stem Cell Transplant are not eligible for enrollment

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: None): Complete blood counts (CBCs), reticulocytes, differential, lactate dehydrogenase (LDH), bilirubin and alanine transaminases (ALTs), cystatin C, blood urea nitrogen (BUN), Creatinine, fetal hemoglobin (HbF), pit counts, Howell Jolly Body (HJB), and urine microalbumin:creatinine ratio were collected at study entry, annually, and exit to Follow-Up Study II. Variable-diversity-joining (VDJ) and a stored blood sample were collected at study entry and study exit. Additional tests that include liver/spleen scan, abdominal sonogram, pulmonary function testing, magnetic resonance imaging (MRI) / magnetic resonance angiography (MRA), cardiac echocardiogram, or neuropsychology testing were collected once during the study when the child was 10 years old.
- Passive (Type: None): Complete blood counts (CBCs), reticulocytes, differential, lactate dehydrogenase (LDH), bilirubin and alanine transaminases (ALTs), cystatin C, blood urea nitrogen (BUN), Creatinine, fetal hemoglobin (HbF), pit counts, Howell Jolly Body (HJB), variable-diversity-joining (VDJ), urine microalbumin:creatinine ratio and a stored blood sample were collected at study entry and exit to Follow-Up Study II. Additional tests that include liver/spleen scan, abdominal sonogram, pulmonary function testing, MRI/MRA, cardiac echocardiogram, or neuropsychology testing were collected as part of clinical care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is HIV positive~* Patient agrees to use (or have their partner use) birth control as defined by the study doctor~Exclusion Criteria:~* If female, pregnant or breastfeeding~* Patient has used an investigational agent in the last 30 days~* Patient has acute hepatitis~* Patient has received MK0518 (raltegravir) before~* Patient has used another experimental HIV-integrase inhibitor

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): raltegravir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* idiopathic, familial or associated PAH, WHO group 1~* NYHA class II or III~* clinically stable with optimized PAH treatment for at least 3 months~* no or minimal evidence of fluid overload or volume depletion, with or without diuretic treatment~* age \> 18 years~* mean pulmonary artery pressure (mPAP) \> 25 mmHg~* 6 minute walk distance (6MWD) over 100m~Exclusion Criteria:~* Structural heart disease unrelated to PAH~* Recent (\<3 months) treatment with an intravenous positive inotropic agent~* current use of β-blockers~* history of reactive airways disease~* history of adverse reaction to β-blockers~* heart block on ECG or resting heart rate \< 60 bpm~* cardiac index \< 1.8 l/min/m2~* systemic hypotension (systolic pressure \< 90 mmHg)~* pulmonary capillary wedge pressure \> 15 mmHg~* inability to give informed consent~* contraindications to CT and/or PET scanning~* coagulopathy (INR\>1.5 or platelet count\<50000/mm3)~* severe renal insufficiency (creatinine clearance \<30 ml/min/m2)~* malignancy or any co-morbidity limiting survival or conditions predicting inability to complete the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- carvedilol (Type: EXPERIMENTAL): Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-medication With Alfentanil vs Placebo During ECT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> /=18 years~* Males or females~* Anticipating electroconvulsive therapy to treat refractory depressive disorder~Exclusion Criteria:~* Under the age of 18~* Allergy to alfentanil~* Allergy to other standard anesthetic medications utilized in the course of ECT (glycopyrrolate, methohexital, and succinylcholine)~* History of malignant hyperthermia~* History of severe airway obstruction, bronchospasm or laryngospasm~* History of recent myocardial infarction, ventricular arrhythmia~* Adverse reaction to ECT requiring premedication with lidocaine or atropine~* Non-English speaking~* Patients unable to consent for themselves~* Current pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alfentanil (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients have Type 2 Diabetes Mellitus and have laboratory results that are within the values established by the study such as an Hemoglobin A1c (HbA1c) \>=7.5% and \<=11% and a Fasting Plasma Glucose (FPG) \>=130 mg/dL and \<=280 mg/dL~Exclusion Criteria :~* Patients have Type 1 Diabetes Mellitus or required insulin therapy within the past 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): sitagliptin 100 mg
- 2 (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Systemic Sclerosis diagnosed by the American College of Rheumatology consensus statement including any of the following:~   * Limited~  * Diffuse~  * Sine Scleroderma~2. Patients must be willing and able to undergo right heart catheterization with lower extremity cycle ergometry~3. Mean pulmonary artery pressure (mPAP) \> 30mmHg with exercise; PCWP ≤ 15mmHg on RHC at rest~4. Men and women, ages 18 years of age or older~5. Standard adjunctive medications will be allowed concurrently in this study at the discretion of the treating pulmonologist and rheumatologist, including digoxin, diuretics, anticoagulants (e.g. warfarin), stable immunosuppression or other anti-fibrotic therapy for at least one month prior to enrollment~Exclusion Criteria:~1. Resting PAH (mPAP \> 25mmHg) on right heart catheterization~2. Other known causes of PAH including prior venous thromboembolism, HIV infection, chronic liver disease with portal hypertension, left ventricular systolic dysfunction (e.g. LVEF \< 40%), and congenital causes of PAH~3. Severe hepatic disease precluding the use of ambrisentan (AST/ALT ≥3x ULN).~4. Women who are pregnant or breastfeeding.~5. Concurrent therapy with a prostanoid or prostanoid analogue, PDE5 inhibitors, or enrolled in another active clinical study.~6. Use of any prostacyclin or endothelial receptor antagonist (ERA) within 30 days before study entry.~7. Bed or wheel chair bound or a baseline 6-Minute Walk distance (6MWD) less than 150 meters.~8. Childbearing capable women who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period.~9. New York Heart Association (NYHA) Classification: Class IV~10. Renal dysfunction (serum creatinine \>2.5mg/dL).~11. Uncontrolled sleep apnea.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ambrisentan (Type: EXPERIMENTAL): ambrisentan dosed at either 5mg or 10mg orally once per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Web-based Interpretation Training For Anxiety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~The target population will be adults age 18 and over who score in the moderate to extremely severe anxiety range (i.e., 10 or higher) on the Depression, Anxiety, Stress Scales - Short Form: Anxiety Subscale and have regular access to the Internet.~Exclusion Criteria:~None listed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Positive Training+Anxious Imagery Prime (Type: EXPERIMENTAL): Positive Cognitive Bias Modification - Interpretation training paired with a preceding Anxious Imagery Prime
- Positive Training+Neutral Imagery Prime (Type: EXPERIMENTAL): Positive Cognitive Bias Modification - Interpretation training paired with a preceding Neutral Imagery Prime
- 50/50 Training+Anxious Imagery Prime (Type: ACTIVE_COMPARATOR): 50/50 Cognitive Bias Modification - Interpretation (half positive \& half negative scenarios) paired with a preceding Anxious Imagery Prime
- 50/50 Training+Neutral Imagery Prime (Type: ACTIVE_COMPARATOR): 50/50 Cognitive Bias Modification - Interpretation (half positive \& half negative scenarios) paired with a preceding Neutral Imagery Prime
- No Scenario+Anxious Imagery Prime (Type: OTHER): No scenarios paired with a preceding Anxious Imagery Prime
- No Scenario+Neutral Imagery Prime (Type: OTHER): No scenarios paired with a preceding Neutral Imagery Prime

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary progressive multiple sclerosis (according to revised McDonald criteria)~* EDSS at screening from 3 to 6.5 points~* Disease duration from onset of MS symptoms less than (\<) 15 years if EDSS greater than (\>) 5.0; \<10 years if EDSS greater than or equal to (\>/=) 5.0~* Sexually active male and female participants of reproductive potential must use two methods of contraception throughout the study treatment phase and for 48 weeks after the last dose~Exclusion Criteria:~* History of relapsing remitting MS, secondary progressive, or progressive relapsing MS at screening~* Inability to complete an MRI (contraindications for MRI)~* Known presence of other neurologic disorders~* Known active infection or history of or presence of recurrent or chronic infection~* History of cancer, including solid tumors and hematological malignancies (except for basal cell, in situ squamous cell carcinomas of the skin and in situ carcinoma of the cervix that have been excised and resolved)~* Previous treatment with B-cell targeted therapies (e.g. rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab)~* Any previous treatment with lymphocyte trafficking blockers, with alemtuzumab, anti-cluster of differentiation 4 (CD4), cladribine, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation~* Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: EXPERIMENTAL): Participants with primary progressive multiple sclerosis (PPMS) received placebo matched to ocrelizumab at a schedule interval of 24 weeks up to at least 120 weeks.
- Ocrelizumab 600 mg (Type: PLACEBO_COMPARATOR): Participants with PPMS received ocrelizumab as two IV infusions of 300 mg separated by 14 days at a scheduled interval of every 24 weeks up to at least 120 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite (HDM) Tablets in Allergic Rhinitis Environment Exposure Chamber Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* history of HDM rhinitis allergy for \> 1 year~* sensitized to D. pteronyssinus and/or D. farinae~* RTSS \>= 6 at least 2 time points during allergen challenge session~Exclusion Criteria:~* co sensitization to other allergen than HDM~* FEV1 \< 80%~* Asthma GINA \> 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 100IR (Type: EXPERIMENTAL): None
- 300IR (Type: EXPERIMENTAL): None
- 500IR (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Smoking Cessation Treatment for Methadone Maintenance Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* English speaking~* Smoked at least 100 cigarettes/lifetime~* Smokes 5 or more cigarettes per day~* Interested in quitting smoking (preparation or contemplation state of change)~* Enrolled in Einstein/Montefiore methadone program for 3 or more months~* Stable methadone dose for 2 weeks~* Agree to use contraception throughout the trial (among women with reproductive potential)~* Willing to participate in all study components~* Able to provide informed consent~Exclusion Criteria:~* Serious or unstable HIV/AIDS, liver, cardiovascular, or pulmonary disease~* Psychiatric instability~* Women who are pregnant, breastfeeding, or contemplating pregnancy~* Creatinine clearance less than 30 mL/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Varenicline (Type: EXPERIMENTAL): Drug treatment in combination with telephone quitline referral and brief individual counseling based on PHS guidelines at weeks 2, 4, 8, and 12
- Placebo (Type: PLACEBO_COMPARATOR): Matched placebo capsules in combination with telephone quitline referral and brief individual counseling based on PHS guidelines at weeks 2, 4, 8, and 12

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be a pre-menopausal woman between 18 and 50 years inclusive.~* Have a Body Mass Index (BMI) ≥ 18 and ≤ 40.~* Have FSH levels ≤ 20 mIU/mL~* Have excessive uterine bleeding due to myoma.~* Have regular menstrual cycles~* Have a myomatous uterus \< 16 weeks with at least one myoma ≥ 3 cm in diameter.~* If of childbearing potential the subject must be practicing a non-hormonal method of contraception.~Exclusion Criteria:~* Has a history of or current uterine, cervical, ovarian or breast cancer.~* Has a history of or current endometrium atypical hyperplasia or adenocarcinoma.~* Has a known severe coagulation disorder.~* Has a history of or current treatment for myoma with a Selective Progesterone Receptor Modulator (SPRM).~* Has abnormal hepatic function at study entry.~* Has a positive pregnancy test, is nursing or planning a pregnancy during the course of the study.~* Has a current (within twelve months) problem with alcohol or drug abuse.~* Is currently enrolled in an investigational drug or device study or has participated in such a study within the last 30 days.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Ulipristal acetate (PGL4001) 5mg (Type: EXPERIMENTAL): All subjects will be asked to take a 150mg size tablet (PGL4001 5mg or matching placebo: placebo 5) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 150mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.
- Ulipristal acetate (PGL4001) 10mg (Type: EXPERIMENTAL): All subjects will be asked to take a 300mg size tablet (PGL4001 10mg or matching placebo: placebo 10 ) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 300mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nuedexta in Treatment-Resistant Major Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants, 18-65 years of age;~* Current primary Axis I diagnosis of major depressive disorder according to DSM-IV-TR criteria as determined by a psychiatrist and confirmed with the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID);~* Current treatment-resistant depression defined by a history of inadequate response to a minimum of 2 adequate antidepressant treatment trials determined by patient history and chart review and confirmed with the Antidepressant Treatment History Form (ATHF);~* Participants must be willing to discontinue treatment with concomitant medications that are disallowed by the study protocol;~* Participants must have a level of understanding of the English language sufficient to agree to all tests and examinations required by the study and must be able to participate fully in the informed consent process.~Exclusion Criteria:~* Lifetime diagnosis of schizophrenia or any psychotic disorder, bipolar disorder, pervasive developmental disorders or mental retardation~* Diagnosis of a substance use disorder within the past 1 year ;~* Female participants who are pregnant, nursing, for may become pregnant;~* Any unstable medical illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease); endocrinologic, neurologic (including history of severe head injury), immunologic, or hematologic disease;~* Participants with clinically significant abnormalities of laboratories, physical examination, or ECG;~* Prolonged QT interval, congenital long QT syndrome, history suggestive of torsades de pointes, or heart failure;~* Complete atrioventricular (AV) block without implanted pacemaker, or patients at high risk of complete AV block~* Participants with a history of quinidine, quinine or mefloquine-induced thrombocytopenia, hepatitis, or other hypersensitivity reactions;~* Participants judged to be at serious suicidal risk by the PI;~* Concomitant use with quinidine, quinine, or mefloquine;~* Participants with known hypersensitivity to dextromethorphan;~* Use with an MAOI or within 14 days of stopping an MAOI;~* Concomitant use with drugs that prolong QT interval and are metabolized by CYP2D6

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Nuedexta (dextromethorphan/quinidine) (Type: EXPERIMENTAL): 45/10 mg every 12 hours x 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete